Article Sidebar

Submitted
Apr 17, 2021
Published
Apr 17, 2021
Download
PDF
Statistic
Read Counter : 40 Download : 26

Main Article Content

Abstract

Background: Pneumonia is a common illness having significant morbidity and mortality. Irrational use of antibiotics in the treatment of pneumonia has led to antibiotic resistance, over prescribing and increased cost of treatment. Therefore, the present study was undertaken to evaluate the trends of antimicrobial prescription in community acquired pneumonia.


Aim: The present study was undertaken with the aim of studying the pattern of use of antimicrobials in community acquired pneumonia.


Materials and Methods: All the antimicrobial containing prescriptions of community acquired pneumonia were monitored. Data from the 80 prescriptions was entered into data entry forms. The number of antimicrobials per prescription, various groups of antibiotics and combinations of antibiotics used for the treatment of community acquired pneumonia, route of administration of antibiotics, duration of antibiotic therapy and length of hospital stay in in-patients was analysed.


Results:In the present study it was observed that community acquired pneumonia was most common in the age group of 42-60 years and the disease was more prevalent in males as compared to females. In the present study 58.75% were in-patients and 41.25% were out-patients. Study showed that 83.75% of the patients received the treatment for 7 days and 16.25% of the patients received the treatment for 14 days. For administration of antibiotics oral route was used in 42.5% of patients and intravenous route was used in 57.5% of patients. Azithromycin was most commonly used antibiotic and combination therapy was given in all the patients and none of the patient was treated with single antibiotic. In the present study most commonly used combination was amoxicillin-azithromycin given in 34 patients. Three antibiotics were given in about 47.5% of patients and two antibiotics were given in 52.5% of patients.

Keywords

Community acquired pneumonia antimicrobials overprescribing antibiotic resistance

Article Details

How to Cite
Payalpreet, Harinder Singh, Vijay K. Sehgal, Anita K. Gupta, & Vishal Chopra. (2021). Study the pattern of use of antimicrobials in community acquired pneumonia. International Journal of Research in Pharmacology & Pharmacotherapeutics, 4(1), 69-76. https://doi.org/10.61096/ijrpp.v4.iss1.2015.69-76
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX

References

  1. [1] Bartlett JG, Dowell SF, Mandell LA, File TM, Musher DM, Fine MJ. Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America. Clin Infect Dis. 2000;31:347-82.
  2. [2] Mandell LA, Bartlett JG, Dowell SF, File TM, Musher DM, Whitney C. Infectious Diseases Society of America. Update of practice guidelines for the management of community-acquired pneumonia in immuno competent adults. Clin Infect Dis. 2003;37:1405-33.
  3. [3] Mason C, Nelson S. Pulmonary host defences: Implications for therapy. Clin Chest Med. 1999;20:475-88.
  4. [4] Welsh D, Mason C. Host defence in respiratory infections. Med Clin North Am. 2001;85:1329-47.
  5. [5] Mandell LA, Wunderink R. Pneumonia. In : Longo DL, Kasper DL, Jameson JL, Fauci AS, Hauser SL, Loscalzo J. (eds.) Harrison’s Principles of Internal Medicine. (18thedn.) New York: McGraw- Hill; 2011;2130-41.
  6. [6] Niederman MS, Mandell LA, Anzueto A, Bass, JB, Broughton WA, Campbell GD et al. American Thoracic Society. Guidelines for the management of adults with community-acquired pneumonia: Diagnosis, assessment of severity, antimicrobial therapy and prevention. Am J RespirCrit Care Med. 2001;163:1730-54.
  7. [7] Dean NC, Silver MP, Bateman KA, James B, Hadlock CJ, Hale D. Decreased mortality after implementation of a treatment guideline for community-acquired pneumonia. Am J Med. 2001;110:451–7.
  8. [8] Capelastegui A, Espana PP, Quintana JM. Improvement of process-of-care and outcomes after implementing a guideline for the management of community-acquired pneumonia: a controlled before-and-after design study. Clin Infect Dis. 2004; 39:955–63.
  9. [9] Guleria R, Kumar J. Management of community acquired pneumonia. JAPI 2012;60:21-22.
  10. [10] Lim WS, Van der Eerden MM, Laing R, Boersma WG, Karalus N, Town GI et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003; 58:377–82.
  11. [11] Man SY, Lee N, Ip M. Prospective comparison of three predictive rules for assessing severity of community-acquired pneumonia in Hong Kong. Thorax 2007;62:348–53.
  12. [12] Gupta D, Agarwal R, Aggarwal AN,Singh N, Mishra N, Khilnani GC et al. Guidelines for diagnosis and management of community and hospital-acquired pneumonia in adults: Joint ICS/NCCP recommendations. Lung India 2012;29:27-62.
  13. [13] Prasad R. Community acquired pneumonia: clinical manifestations. JAPI 2012;60:10-12.
  14. [14] Pimentel LP, McPherson SJ. Community-acquired pneumonia in the emergency department: a practical approach to diagnosis and management. Emerg Med Clin North Am. 2003;21:395-420.
  15. [15] Andrews J, Nadjm B, Gant V. Community-acquired pneumonia. Curr Opin Pulm Med. 2003;9:175-180.
  16. [16] Foy HM. Rates of pneumonia during influenza epidemics in Seattle, 1964 to 1975. JAMA 1979;241(3): 253-8.
  17. [17] Marrie TJ. Factors associated with death among adults <55 years of age hospitalized for community-acquired pneumonia. Clinical Infectious Diseases 2003;36(4):413-21.